PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).

NCT ID: NCT07025681

Last Updated: 2025-06-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-24
• Study Completion Date: 2025-12-31

Brief Summary

Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Erythropoietin, a 165 amino acid glycoprotein manufactured by recombinant DNA technology, has the same biological effects as endogenous erythropoietin. Erythropoietin binds to the surface receptor of erythroid precursor cells and activates signal transduction pathways that interfere with apoptosis and stimulates erythroid cell proliferation. Recombinant human erythropoietin is a substitute for the deficiency observed in CKD, therapy of anemia often involves many other issues such as Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy, Anemic patients (hemoglobin > 10 to < 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions, Anemia related to therapy with zidovudine in HIV-infected patients are also needed to be considered in order to effectively correct anemia, reduce costs and minimize side effects.

Detailed Description

In this study, 56 healthy adult volunteers will participate in a randomized, double-blinded, balanced, two-treatment, two-period, two-sequence, single-dose crossover trial. Each subject will receive a single subcutaneous injection of either Erythropoietin 4000 IU manufactured by Incepta Pharmaceuticals Ltd (test product) or Eprex 4000 IU manufactured by Janssen-Cilag Ltd (reference product) under fasting conditions, with a 28-day washout period between doses. The primary aim of the study is to compare the pharmacokinetic and pharmacodynamic profiles of the two products. Additionally, the study will assess immunogenicity by measuring serum anti-drug antibodies (ADA) and evaluate the safety of both formulations throughout the study duration.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Erythropoietin 4000 IU Injection of Incepta Pharmaceuticals Ltd

Erythropoietin 4000 IU Injection, subcutaneous injection manufactured by Incepta Pharmaceuticals Ltd will be administered.

Group Type: EXPERIMENTAL

Erythropoietin alfa

Intervention Type: BIOLOGICAL

Erythropoietin 4000 IU Injection, for subcutaneous injection.

Eprex 4000 by Janssen-Cilag Ltd

Eprex 4000, subcutaneous injection manufactured by Janssen-Cilag Ltd will be administered.

Group Type: ACTIVE_COMPARATOR

Erythropoietin alfa

Intervention Type: BIOLOGICAL

Erythropoietin 4000 IU Injection, for subcutaneous injection.

Interventions

Erythropoietin alfa

Erythropoietin 4000 IU Injection, for subcutaneous injection.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• • Age ≥ 18 years.

• BMI of 18.0-30.0kg/m2.
• Voluntarily participants who agree to observe the precautions in writing after receiving a complete explanation of this trial.
• Willingness and ability to undertake all scheduled visits and assessments.
• Subject who have no evidence of underlying disease during screening, medical history and whose physical examination is performed within 28 days prior to commencement of the study.
• Subjects whose screening laboratory values are within normal limits or considered by the Investigator to be of no clinical significance.
• Non-smokers, ex-smokers and light smokers can be included in the study. "Light smokers are defined as someone smoking < 10 cigarettes per day, ex-smokers as someone who completely stopped smoking for at least 03 months.
• No alcohol dependence, alcohol abuse or drug abuse (Amphetamines, Cocaine, Tetra Hydro Cannabinoids, Benzodiazepines, Barbiturates and Opioids) within the past one year.
• Subjects should not have consumed grape fruit juice or its products 72 hours before dosing and throughout the study periods.
• For Female Subjects:

1. Subjects having negative urine pregnancy test.

2. Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the Investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

3. Postmenopausal for more than 1 year.

4. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).

Exclusion Criteria

• • Subjects with any previous exposure to erythropoiesis stimulating agents.

• History of clinically significant illness related to liver (including viral hepatitis), kidney, nervous system, immune system, respiratory system, endocrine system, cardiovascular system, blood system and tumor as well as mental illness (mood disorder, obsessive-compulsive disorder, etc.)
• Hypersensitivity or clinically significant hypersensitivity to the drug (e.g. aspirin, antibiotics, etc.)
• Those whose results meet more than one of the followings in the screening including re-test; Hemoglobin level below 12g/dL or over 17g/dL, Ferritin level below 21.8ng/mL, Transferrin level below 190mg/dL, Reticulocyte level >2.5%, erythrocytes level > 5.2x 106/mm3, platelets or serum potassium level over normal range.
• Positive on the HIV antibody, HBsAg, HCV (Hepatitis C Virus) antibody tests.
• Those whose vital signs measured in sitting position after resting over 3 minutes meet more than one of the following; Systolic BP below 90mmHg or over 160mmHg, Diastolic BP below 50mmHg or over 100mmHg, Pulse rate over 100.
• Those who received the following diagnosis within 6 months prior to the screening; Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all kinds), Chronic or uncontrollable inflammatory diseases (e.g., rheumatoid arthritis, systemic erythematosus)
• Those who participated other clinical trials and was administered other drugs within 3 months prior to the scheduled dose.
• Those who bled over 400mL or donated blood within 8 weeks prior to the scheduled first dose.
• Those who are considered inappropriate for the trial by the trial investigator based on the result of clinical laboratory test or due to other reasons.
• Employees of Investigational sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Institute for Developing Science and Health Initiatives, Bangladesh

OTHER

Sponsor Role: collaborator

Incepta Pharmaceuticals Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr. Umme Kulsum

Role: PRINCIPAL_INVESTIGATOR

Institute for developing Science and Health initiatives (ideSHi), Dhaka-1206, Bangladesh

Locations

Universal Medical College and Hospital

Dhaka, Dhaka Division, Bangladesh

Site Status: RECRUITING

Countries

Bangladesh

Central Contacts

Faez Ahmed

Role: CONTACT

faez@inceptapharma.com

+8801714086066 ext. +88028891688

References

Yan X, Lowe PJ, Fink M, Berghout A, Balser S, Krzyzanski W. Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. J Clin Pharmacol. 2012 Nov;52(11):1624-44. doi: 10.1177/0091270011421911. Epub 2011 Dec 12.

Reference Type: BACKGROUND

PMID: 22162538 (View on PubMed)

Yoon S, Rhee SJ, Heo SJ, Oh TY, Yoon SH, Cho JY, Lee S, Yu KS. Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(R) and Eprex(R) following a single subcutaneous administration in healthy male volunteers. Drug Des Devel Ther. 2017 Oct 27;11:3127-3135. doi: 10.2147/DDDT.S142673. eCollection 2017.

Reference Type: BACKGROUND

PMID: 29138535 (View on PubMed)

Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008 Dec;36(12):1573-84. doi: 10.1016/j.exphem.2008.08.003. Epub 2008 Oct 14.

Reference Type: BACKGROUND

PMID: 18922615 (View on PubMed)

Rashidi A, Garimella PS, Al-Asaad A, Kharadjian T, Torres MN, Thakkar J. Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease. Adv Chronic Kidney Dis. 2022 Mar;29(2):180-187.e1. doi: 10.1053/j.ackd.2022.03.005.

Reference Type: BACKGROUND

PMID: 35817525 (View on PubMed)

Portoles J, Martin L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne). 2021 Mar 26;8:642296. doi: 10.3389/fmed.2021.642296. eCollection 2021.

Reference Type: BACKGROUND

PMID: 33842503 (View on PubMed)

Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013 Oct;40(5):302-9. doi: 10.1159/000356193. Epub 2013 Jul 19.

Reference Type: BACKGROUND

PMID: 24273483 (View on PubMed)

Other Identifiers

2024/CT/01

Identifier Type: -

Identifier Source: org_study_id